TOP HEADLINES

Featured Story

  • Study: LDL, omega-3 nano-strategy eliminates liver cancer cells in rats

    There's been a considerable amount of controversy over the past decade whether omega-3 fatty acids can actually promote better health and guard against cancer. But a researcher at UT Southwestern says he has developed a nanoparticle treatment out of LDL and omega-3 that was able to eliminate liver cancer cells in rats while leaving healthy cells unharmed.

Oxford team fingers an inflammatory protein as a trigger for cancer

Researchers from Oxford University working on a protein named PAD4 have made new tracks in identifying its role in cancer, spotlighting a new therapeutic strategy for cancer drug hunters.

CRUK scientists ID a key player behind the spread of breast cancer cells

The interaction between breast cancer cells and a receptor protein called EPHA2 helps explain how the cancer spreads through the body, according to a prominent group of investigators looking for new ways to fight cancer.

NIH researchers find genomic signature common in 5 types of cancer

Scientists hailing from the National Institutes of Health have uncovered genomic signatures that are shared across a number of different cancers. This discovery could serve as a useful biomarker to flag cancer at an earlier stage, paving the way to earlier treatment that may help improve survival rates.

Sequencing deer tick genome may help stop Lyme disease one day

Looking for new ways to stop the spread of Lyme disease, a large group of scientists have completed sequencing the genome of the deer tick, which spreads the disease.

Study: LDL, omega-3 nano-strategy eliminates liver cancer cells in rats

There's been a considerable amount of controversy over the past decade whether omega-3 fatty acids can actually promote better health and guard against cancer. But a researcher at UT Southwestern says he has developed a nanoparticle treatment out of LDL and omega-3 that was able to eliminate liver cancer cells in rats while leaving healthy cells unharmed.

MORE NEWS

From Our Sister Sites

FierceBiotech

FiercePharma 's Eric Palmer and FierceBiotech 's Damian Garde discuss a bizarre congressional hearing, how biotech's slump affects the buyout climate, and a major development in the world of biosimilars.

FiercePharmaAsia

A phase III trial for the Alecensa lung cancer treatment developed by Tokyo-based Chugai Pharmaceutical will be stopped early based on the recommendation of an independent data monitoring group because the drug has met its primary endpoint and showed that patients were living "significantly longer" with the treatment when compared to crizotinib.